Stock Price Quote

ABBOTT INDIA LTD.

NSE : ABBOTINDIABSE : 500488ISIN CODE : INE358A01014Industry : Pharmaceuticals & DrugsHouse : Abbott India - MNC
BSE28030.55-89.85 (-0.32 %)
PREV CLOSE ( ) 28120.40
OPEN PRICE ( ) 28120.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 677
TODAY'S LOW / HIGH ( )27810.00 28190.35
52 WK LOW / HIGH ( )25260.2 35921.55
NSE27985.00-90 (-0.32 %)
PREV CLOSE( ) 28075.00
OPEN PRICE ( ) 28080.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 27985.00 (15)
VOLUME 11892
TODAY'S LOW / HIGH( ) 27770.00 28245.00
52 WK LOW / HIGH ( )25325 37000
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 22-08 1944
Management Info
Munir Shaikh - Chairman Kartik Rajendran - Managing Director
Registered Office

Address Unit No. 3,Corporate Park,Sion Trombay Road,
Mumbai,
Maharashtra-400071

Phone 022-50461000 / 2000 / 67978888

Email webmasterindia@abbott.com / investorrelations.india@abbott.com

Website www.abbott.co.in

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

07Nov Abbott India informs about newspaper p
Pursuant to Regulation 47 of the Securities and Exchange Board of India..
01Aug Abbott India informs about disclosure
In the matter of compounding application filed by the Company with the R..
29Jul Abbott India informs about newspaper
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
26Jun Abbott India informs about closure of
Abbott India has informed that, in accordance with the provisions of the..
19Jun Abbott, MSD Pharmaceuticals enter into
Abbott and MSD Pharmaceuticals have entered into partnership for distrib..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit4152.714144.4
Gross Profit 5459.3 18869.5
Operating Profit 5721.219701.8
Net Sales 17571.564091.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE)
peergroup  5694.85 (1.04%)
M.Cap ( in Cr)9418.57
Haleos Labs (BSE)
peergroup  1385.00 (3.40%)
M.Cap ( in Cr)418.73
Pfizer (BSE)
peergroup  5027.50 (0.90%)
M.Cap ( in Cr)23031.01
Venus Remedies (BSE)
peergroup  786.50 (5.00%)
M.Cap ( in Cr)1051.31
Ajanta Pharma (BSE)
peergroup  2655.30 (1.37%)
M.Cap ( in Cr)33097.95

Shareholding Pattern

PROMOTERS 74.99%
MUTUAL FUNDS/UTI 7.78%
NON-INSTITUTION 15.75%
FI/BANKS/INSURANCE 1.07%
GOVERNMENT 0%
FII 0%

About Abbott India Ltd.

Abbott India Ltd. was incorporated in the year 1944. Its today's share price is 28030.55. Its current market capitalisation stands at Rs 59392.44 Cr. In the latest quarter, company has reported Gross Sales of Rs. 65999 Cr and Total Income of Rs.66872 Cr. The company's management includes Alison Davies, Kaiyomarz Marfatia, Shalini Kamath, Anisha Motwani, Sudarshan Jain, Ambati Venu, Kartik Rajendran, Munir Shaikh, Sangeeta Shetty.

It is listed on the BSE with a BSE Code of 500488 , NSE with an NSE Symbol of ABBOTINDIA and ISIN of INE358A01014. It's Registered office is at Unit No. 3,Corporate Park,Sion Trombay RoadMumbai-400071, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, Deloittee Haskins & Sells, SRBC & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.